Abstract
We developed a label-free Raman method for monitoring the therapeutic benefit of temozolomide in glioblastoma by whole-cell biochemical hyperspectral imaging for detecting molecular processes occurring in normal and tumorous brain cells at the level of isolated organelles. Our approach allows biochemical compositional mapping of lipid droplets, mitochondria, and nucleus in single cells, monitoring intracellular alterations upon using different doses of temozolomide, a drug normally used to treat gliomas. We detected Raman spectral changes in DNA, proteins and lipids. The viability (% of control) of high grade tumorous cells of glioblastoma U87MG after incubation for 24 and 48 h with temozolomide has been measured. The Raman spectral changes in separate organelles of glioblastoma cells helps to elucidate the detailed mechanisms of action of temozolomide.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
